Vivesto AB Stock price

Equities

VIVE

SE0000722365

Pharmaceuticals

Delayed Nasdaq Stockholm 07:44:06 2024-03-28 am EDT 5-day change 1st Jan Change
0.3105 SEK -2.82% Intraday chart for Vivesto AB -2.82% -23.80%
Sales 2021 28.87M 2.7M Sales 2022 3.04M 285K Capitalization 234M 21.87M
Net income 2021 -133M -12.45M Net income 2022 -357M -33.43M EV / Sales 2021 37.7 x
Net cash position 2021 86.84M 8.13M Net cash position 2022 134M 12.58M EV / Sales 2022 32.6 x
P/E ratio 2021
-8.86 x
P/E ratio 2022
-0.6 x
Employees 14
Yield 2021 *
-
Yield 2022
-
Free-Float 61.42%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Vivesto AB

1 day-2.82%
1 week-2.82%
Current month+10.70%
1 month+3.67%
3 months-36.83%
6 months+38.93%
Current year-23.80%
More quotes
1 week
0.31
Extreme 0.305
0.34
1 month
0.26
Extreme 0.257
0.45
Current year
0.26
Extreme 0.257
0.55
1 year
0.16
Extreme 0.1616
0.91
3 years
0.16
Extreme 0.1616
3.98
5 years
0.16
Extreme 0.1616
11.45
10 years
0.16
Extreme 0.1616
24.40
More quotes
Managers TitleAgeSince
Chief Executive Officer 66 23-01-22
Director of Finance/CFO 64 20-11-30
Chief Tech/Sci/R&D Officer 55 21-02-28
Members of the board TitleAgeSince
Chairman 44 19-03-18
Director/Board Member 59 19-09-25
Director/Board Member 41 22-05-24
More insiders
Date Price Change Volume
24-03-28 0.3105 -2.82% 269,270
24-03-27 0.3195 -2.29% 678,342
24-03-26 0.327 +3.32% 595,626
24-03-25 0.3165 -0.78% 1,552,151
24-03-22 0.319 -0.16% 557,901

Delayed Quote Nasdaq Stockholm, March 28, 2024 at 07:44 am EDT

More quotes
Vivesto AB, formerly Oasmia Pharmaceutical AB is a Swecen-based pharma company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company has a growing portfolio of projects in the clinical phase focused on advanced cancer. Apealea (paclitaxel micellar) is being developed for patients with ovarian cancer through a partnership with Elevar Therapeutics, Inc. Other development programs include Cantrixil, a clinical program in advanced ovarian cancer, and docetaxel micellar, which is being developed for widespread prostate cancer. Vivesto's patented technology platform is developed to improve the water solubility, efficacy and safety of drugs.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Vivesto AB - Nasdaq Stockholm